Florbetapir (18F)

# Overview
Florbetapir (18F) (trade name AMYViD; also known as florbetapir-fluorine-18 or 18F-AV-45) is a PET scanning radiopharmaceutical compound containing the radionuclide fluorine-18, recently FDA approved as a diagnostic tool for Alzheimer's disease. Florbetapir, like Pittsburgh compound B (PiB), binds to beta-amyloid, but due to its use of fluorine-18 has a half-life of 110 minutes, in contrast to PiB's radioactive half life of 20 minutes. Wong et al. found that the longer life allowed the tracer to accumulate significantly more in the brains of people with AD, particularly in the regions known to be associated with beta-amyloid deposits.
One review predicted that amyloid imaging is likely to be used in conjunction with other markers rather than as an alternative.

# Development of florbetapir
Since the disease was first described by Alois Alzheimer in 1906, the only certain way to determine if a person indeed had the disease was to perform an autopsy on the patient's brain to find distinctive spots on the brain that show the buildup of amyloid plaque. Doctors must diagnose the disease in patients with memory loss and dementia based on symptoms, and as many as 20% of patients diagnosed with the disease are found after examination of the brain following death not to have had the condition. Other diagnostic tools, such as analysis of cerebrospinal fluid, magnetic resonance imaging scans looking for brain shrinkage and PET scans looking at how glucose was used in the brain, had all been unreliable.
The development of florbetapir built on research done by William Klunk and Chester Mathis who had developed a substance they called Pittsburgh compound B as a means of detecting amyloid plaque, after analyzing 400 prospective compounds and developing 300 variations of the substance that they had discovered might work. In 2002, a study performed in Sweden on Alzheimer's patients was able to detect the plaque in PET brain scans. Later studies on a control group member without the disease did not find plaque, confirming the reliability of the compound in diagnosis. While the tool worked, Pittsburgh compound B relies on the use of carbon-11, a radioactive isotope with a half-life of 20 minutes that requires the immediate use of the material prepared in a cyclotron.
Avid Radiopharmaceuticals was established by Daniel Skovronsky in July 2005 with the goal of finding a dye that could be injected into the body, would cross the bloodbrain barrier and attach itself to amyloid protein deposits in the brain. Avid raised $500,000 from BioAdvance, the Biotechnology Greenhouse of Southeastern Pennsylvania, as seed funding toward the development of a biological marker. Once they found a candidate dye, they attached the positron-emitting fluorine-18, a radioactive isotope with a half-life of nearly two hours that is used annually in two million PET scans and that can last for as long as a day when prepared in the morning by cyclotron. The dye had been developed and patented by the University of Pennsylvania and was licensed by Avid.
Initial tests in 2007 on a patient at Johns Hopkins University Hospital previously diagnosed with symptoms of Alzheimer's disease detected plaque in a PET scan in areas where it was typically found in the brain. Further tests found that the scans detected plaque in patients with Alzheimer's, didn't find it in those without the diagnosis and found intermediate amounts in patients with early signs of dementia. The tests found amyloid plaque in 20% of its test patients over age 60 that had been in the normal range, but had performed worse than a control group on tests of mental acuity.
In order to confirm if the dye was accurate in detecting Alzheimer's, an advisory committee at the Food and Drug Administration demanded that the team of Avid, Bayer and General Electric perform a study to test their method. Avid established a study with a group of 35 hospice patients, some that had been diagnosed with dementia and others that had no memory problems. The participants and their families agreed that they would undergo the PET scans and would have their brains autopsied after their death by pathologists. After the study was conducted, Avid received confirmation in May 2010 that the results of the test were successful in distinguishing between those with Alzheimer's and those without the disease.
In results presented in July 2010 to an international conference on Alzheimer's disease held in Hawaii, the company showed that for 34 out of the 35 hospice patients who had been scanned, the initial scan results were confirmed when pathologists counted plaque under a microscope and when a computerized scan of the plaque was performed on material from the autopsied brain. The findings will require review by the FDA to confirm its reliability as a means of diagnosing the disease. If confirmed, the technique would provide a means to reliably diagnose and monitor the progress of Alzheimer's and would allow potential pharmaceutical treatments to be evaluated.
In a study published in January 2011 in the Journal of the American Medical Association, Avid reported on the results of further studies conducted based on 152 test subjects who had agreed to receive the company's PET scans and to have their brains analyzed after death for definitive determination of the presence of amyloid plaques. Of the patients included in the study, 29 who died had autopsies performed on their brains and in all but one the brain autopsy results matched the diagnosis based on the PET scan taken before death. Avid's technique is being used to test the efficacy of Alzheimer's disease treatments being developed by other pharmaceutical firms as a means of determining the ability of the drugs to reduce the buildup of amyloid protein in the brains of living subjects.

# Approval by FDA
On January 20, 2011, an FDA advisory committee unanimously recommended that Avid's PET scan technique be approved for use. The advisory committee included a qualification requiring Avid to develop clear guidelines establishing when the tests had spotted enough of the amyloid plaque to make a diagnosis of Alzheimer's, a task that Avid CEO Daniel M. Skovronsky stated could be resolved in several months.

# Acquisition by Eli Lilly
Avid Radiopharmaceuticals was based at the University City Science Center research campus in Philadelphia, Pennsylvania. The company was the first to bring to market an FDA-approved method that could directly detect the amyloid deposition hallmark pathology of Alzheimer's disease.
Eli Lilly and Company announced on November 8, 2010, that they would acquire Avid for $800 million, $300 million up front and the balance paid later.